Vascular actions of aldosterone

Journal of Vascular Research

Volumn 50, Issue 2, 2013, Pages 89-99

  Briet, Marie ^a   Schiffrin, Ernesto L ^b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Arteries; Endothelial dysfunction; Genomic and nongenomic effects; Inflammation; Oxidative stress; Remodeling; Vascular stiffness; Vasoconstriction

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; ANGIOTENSIN II; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN 1; EPLERENONE; G PROTEIN COUPLED RECEPTOR 30; LCI 699; MINERALOCORTICOID RECEPTOR; SODIUM CHLORIDE; SPIRONOLACTONE; UNCLASSIFIED DRUG;

ADD ON THERAPY; ALDOSTERONE BLOOD LEVEL; ALDOSTERONE RELEASE; ANTIHYPERTENSIVE THERAPY; ARTERIAL STIFFNESS; BIOMECHANICS; BLOOD VESSEL TONE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG EFFECT; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; ESSENTIAL HYPERTENSION; GYNECOMASTIA; HEART FAILURE; HUMAN; HYPERTENSION; HYPERTROPHY; INFLAMMATION; METABOLIC SYNDROME X; MOLECULAR INTERACTION; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; PROTEINURIA; RECEPTOR BINDING; REVIEW; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; VASCULAR ENDOTHELIUM; VASCULAR FIBROSIS; VASCULAR SMOOTH MUSCLE; VASCULITIS; VASOCONSTRICTION;

ADIPOCYTES; ALDOSTERONE; ANGIOTENSIN II; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD VESSELS; CARDIOVASCULAR DISEASES; ENDOTHELIN-1; ENDOTHELIUM, VASCULAR; FIBROSIS; GENE EXPRESSION REGULATION; HUMANS; HYPERTENSION; HYPERTROPHY; METABOLIC SYNDROME X; MINERALOCORTICOID RECEPTOR ANTAGONISTS; MINERALOCORTICOIDS; MUSCLE, SMOOTH, VASCULAR; OXIDATIVE STRESS; RECEPTOR, ENDOTHELIN A; RECEPTORS, MINERALOCORTICOID; RENIN-ANGIOTENSIN SYSTEM; SIGNAL TRANSDUCTION; SODIUM; VASCULITIS; VASOCONSTRICTION;

EID: 84874229170     PISSN: 10181172     EISSN: 14230135     Source Type: Journal    
DOI: 10.1159/000345243     Document Type: Review

References (87)

1. Briet M, Schiffrin EL: Aldosterone: effects on the kidney and cardiovascular system. Nat Rev Nephrol 2010; 6: 261-273.
2. Conn JW: Primary aldosteronism, a new clinical syndrome. J Lab Clin Med 1955; 45: 3-17.
3. Genest J, Lemieux G, Davignon A, Koiw E, Nowaczynski W, Steyermark P: Human arterial hypertension: a state of mild chronic hyperaldosteronism Science 1956; 123: 503-505.
4. Park JB, Schiffrin EL: ET(A) receptor antagonist prevents blood pressure elevation and vascular remodeling in aldosterone-infused rats. Hypertension 2001; 37: 1444-1449.
5. Park JB, Schiffrin EL: Cardiac and vascular fibrosis and hypertrophy in aldosterone-infused rats: role of endothelin-1. Am J Hypertens 2002; 15: 164-169.
6. Benetos A, Lacolley P, Safar ME: Prevention of aortic fibrosis by spironolactone in spontaneously hypertensive rats. Arterioscler Thromb Vasc Biol 1997; 17: 1152-1156.
7. Virdis A, Neves MF, Amiri F, Viel E, Touyz RM, Schiffrin EL: Spironolactone improves angiotensin-induced vascular changes and oxidative stress. Hypertension 2002; 40: 504-510.
8. Mazak I, Fiebeler A, Muller DN, Park JK, Shagdarsuren E, Lindschau C, Dechend R, Viedt C, Pilz B, Haller H, et al: Aldosterone potentiates angiotensin II-induced signaling in vascular smooth muscle cells. Circulation 2004; 109: 2792-2800.
9. Callera GE, Montezano AC, Yogi A, Tostes RC, He Y, Schiffrin EL, Touyz RM: c-Src-dependent nongenomic signaling responses to aldosterone are increased in vascular myocytes from spontaneously hypertensive rats. Hypertension 2005; 46: 1032-1038.
10. Miyata K, Hitomi H, Guo P, Zhang GX, Kimura S, Kiyomoto H, Hosomi N, Kagami S, Kohno M, Nishiyama A: Possible involvement of Rho-kinase in aldosterone-induced vascular smooth muscle cell remodeling. Hypertens Res 2008; 31: 1407-1413.
11. Lacolley P, Labat C, Pujol A, Delcayre C, Benetos A, Safar M: Increased carotid wall elastic modulus and fibronectin in aldosterone-salt-treated rats: effects of eplerenone. Circulation 2002; 106: 2848-2853.
12. Blacher J, Amah G, Girerd X, Kheder A, Ben Mais H, London GM, Safar ME: Association between increased plasma levels of aldosterone and decreased systemic arterial compliance in subjects with essential hypertension. Am J Hypertens 1997; 10: 1326-1334.
13. Safar ME, Cattan V, Lacolley P, Nzietchueng R, Labat C, Lajemi M, de Luca N, Benetos A: Aldosterone synthase gene polymorphism, stroke volume and age-related changes in aortic pulse wave velocity in subjects with hypertension. J Hypertens 2005; 23: 1159-1166.
14. Brilla CG, Weber KT: Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. J Lab Clin Med 1992; 120: 893-901.
15. Calo LA, Puato M, Schiavo S, Zanardo M, Tirrito C, Pagnin E, Balbi G, Davis PA, Palatini P, Pauletto P: Absence of vascular remodelling in a high angiotensin-II state (Bartter's and Gitelman's syndromes): implications for angiotensin II signalling pathways. Nephrol Dial Transplant 2008; 23: 2804-2809.
16. Nakano S, Kobayashi N, Yoshida K, Ohno T, Matsuoka H: Cardioprotective mechanisms of spironolactone associated with the angiotensin-converting enzyme/epidermal growth factor receptor/extracellular signalregulated kinases, NAD(P)H oxidase/lectinlike oxidized low-density lipoprotein receptor-1, and Rho-kinase pathways in aldosterone/salt-induced hypertensive rats. Hypertens Res 2005; 28: 925-936.
17. Rocha R, Martin-Berger CL, Yang P, Scherrer R, Delyani J, McMahon E: Selective aldosterone blockade prevents angiotensin II/saltinduced vascular inflammation in the rat heart. Endocrinology 2002; 143: 4828-4836.
18. Johar S, Cave AC, Narayanapanicker A, Grieve DJ, Shah AM: Aldosterone mediates angiotensin II-induced interstitial cardiac fibrosis via a Nox2-containing NADPH oxidase. FASEB J 2006; 20: 1546-1548.
19. Callera GE, Touyz RM, Tostes RC, Yogi A, He Y, Malkinson S, Schiffrin EL: Aldosterone activates vascular p38MAP kinase and NADPH oxidase via c-Src. Hypertension 2005; 45: 773-779.
20. Callera GE, Yogi A, Briones AM, Montezano AC, He Y, Tostes RC, Schiffrin EL, Touyz RM: Vascular proinflammatory responses by aldosterone are mediated via c-Src trafficking to cholesterol-rich microdomains: role of PDGFR. Cardiovasc Res 2011; 91: 720-731.
21. Iwashima F, Yoshimoto T, Minami I, Sakurada M, Hirono Y, Hirata Y: Aldosterone induces superoxide generation via Rac1 activation in endothelial cells. Endocrinology 2008; 149: 1009-1014.
22. Kasal DA, Barhoumi T, Li MW, Yamamoto N, Zdanovich E, Rehman A, Neves MF, Laurant P, Paradis P, Schiffrin EL: T regulatory lymphocytes prevent aldosterone-induced vascular injury. Hypertension 2012; 59: 324-330.
23. Caprio M, Newfell BG, la Sala A, Baur W, Fabbri A, Rosano G, Mendelsohn ME, Jaffe IZ: Functional mineralocorticoid receptors in human vascular endothelial cells regulate intercellular adhesion molecule-1 expression and promote leukocyte adhesion. Circ Res 2008; 102: 1359-1367.
24. Sun Y, Zhang J, Lu L, Chen SS, Quinn MT, Weber KT: Aldosterone-induced inflammation in the rat heart: role of oxidative stress. Am J Pathol 2002; 161: 1773-1781.
25. Nishizaka MK, Zaman MA, Green SA, Renfroe KY, Calhoun DA: Impaired endothelium-dependent flow-mediated vasodilation in hypertensive subjects with hyperaldosteronism. Circulation 2004; 109: 2857-2861.
26. Blanco-Rivero J, Cachofeiro V, Lahera V, Aras-Lopez R, Marquez-Rodas I, Salaices M, Xavier FE, Ferrer M, Balfagon G: Participation of prostacyclin in endothelial dysfunction induced by aldosterone in normotensive and hypertensive rats. Hypertension 2005; 46: 107-112.
27. Farquharson CA, Struthers AD: Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 2000; 101: 594-597.
28. Garnier A, Bendall JK, Fuchs S, Escoubet B, Rochais F, Hoerter J, Nehme J, Ambroisine ML, De Angelis N, Morineau G, et al: Cardiac specific increase in aldosterone production induces coronary dysfunction in aldosterone synthase-transgenic mice. Circulation 2004; 110: 1819-1825.
29. Favre J, Gao J, Zhang AD, Remy-Jouet I, Ouvrard-Pascaud A, Dautreaux B, Escoubet B, Thuillez C, Jaisser F, Richard V: Coronary endothelial dysfunction after cardiomyocyte-specific mineralocorticoid receptor overexpression. Am J Physiol Heart Circ Physiol 2011; 300:H2035-H2043.
30. Leopold JA, Dam A, Maron BA, Scribner AW, Liao R, Handy DE, Stanton RC, Pitt B, Loscalzo J: Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity. Nat Med 2007; 13: 189-197.
31. Griol-Charhbili V, Fassot C, Messaoudi S, Perret C, Agrapart V, Jaisser F: Epidermal growth factor receptor mediates the vascular dysfunction but not the remodeling induced by aldosterone/salt. Hypertension 2011; 57: 238-244.
32. Schneider SW, Yano Y, Sumpio BE, Jena BP, Geibel JP, Gekle M, Oberleithner H: Rapid aldosterone-induced cell volume increase of endothelial cells measured by the atomic force microscope. Cell Biol Int 1997; 21: 759-768.
33. Oberleithner H, Schneider SW, Albermann L, Hillebrand U, Ludwig T, Riethmuller C, Shahin V, Schafer C, Schillers H: Endothelial cell swelling by aldosterone. J Membr Biol 2003; 196: 163-172.
34. Oberleithner H, Riethmuller C, Ludwig T, Hausberg M, Schillers H: Aldosterone remodels human endothelium. Acta Physiol (Oxf) 2006; 187: 305-312.
35. Hillebrand U, Schillers H, Riethmuller C, Stock C, Wilhelmi M, Oberleithner H, Hausberg M: Dose-dependent endothelial cell growth and stiffening by aldosterone: endothelial protection by eplerenone. J Hypertens 2007; 25: 639-647.
36. Oberleithner H, Riethmuller C, Schillers H, MacGregor GA, de Wardener HE, Hausberg M: Plasma sodium stiffens vascular endothelium and reduces nitric oxide release. Proc Natl Acad Sci USA 2007; 104: 16281-16286.
37. Thum T, Schmitter K, Fleissner F, Wiebking V, Dietrich B, Widder JD, Jazbutyte V, Hahner S, Ertl G, Bauersachs J: Impairment of endothelial progenitor cell function and vascularization capacity by aldosterone in mice and humans. Eur Heart J 2011; 32: 1275-1286.
38. Wu VC, Lo SC, Chen YL, Huang PH, Tsai CT, Liang CJ, Kuo CC, Kuo YS, Lee BC, Wu EL, et al: Endothelial progenitor cells in primary aldosteronism: a biomarker of severity for aldosterone vasculopathy and prognosis. J Clin Endocrinol Metab 2011; 96: 3175-3183.
39. Schiffrin EL, Gutkowska J, Genest J: Effect of angiotensin II and deoxycorticosterone infusion on vascular angiotensin II receptors in rats. Am J Physiol 1984; 246:H608-H614.
40. Schiffrin EL, Franks DJ, Gutkowska J: Effect of aldosterone on vascular angiotensin II receptors in the rat. Can J Physiol Pharmacol 1985; 63: 1522-1527.
41. Hatakeyama H, Miyamori I, Fujita T, Takeda Y, Takeda R, Yamamoto H: Vascular aldosterone: biosynthesis and a link to angiotensin II-induced hypertrophy of vascular smooth muscle cells. J Biol Chem 1994; 269: 24316-24320.
42. Takeda Y, Miyamori I, Yoneda T, Iki K, Hatakeyama H, Blair IA, Hsieh FY, Takeda R: Production of aldosterone in isolated rat blood vessels. Hypertension 1995; 25: 170-173.
43. Ahmad N, Romero DG, Gomez-Sanchez EP, Gomez-Sanchez CE: Do human vascular endothelial cells produce aldosterone Endocrinology 2004; 145: 3626-3629.
44. Fiebeler A, Nussberger J, Shagdarsuren E, Rong S, Hilfenhaus G, Al-Saadi N, Dechend R, Wellner M, Meiners S, Maser-Gluth C, et al: Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage. Circulation 2005; 111: 3087-3094.
45. Xiao F, Puddefoot JR, Barker S, Vinson GP: Mechanism for aldosterone potentiation of angiotensin II-stimulated rat arterial smooth muscle cell proliferation. Hypertension 2004; 44: 340-345.
46. Min LJ, Mogi M, Li JM, Iwanami J, Iwai M, Horiuchi M: Aldosterone and angiotensin II synergistically induce mitogenic response in vascular smooth muscle cells. Circ Res 2005; 97: 434-442.
47. Min LJ, Mogi M, Iwanami J, Li JM, Sakata A, Fujita T, Tsukuda K, Iwai M, Horiuchi M: Cross-talk between aldosterone and angiotensin II in vascular smooth muscle cell senescence. Cardiovasc Res 2007; 76: 506-516.
48. Montezano AC, Callera GE, Yogi A, He Y, Tostes RC, He G, Schiffrin EL, Touyz RM: Aldosterone and angiotensin II synergistically stimulate migration in vascular smooth muscle cells through c-Src-regulated redoxsensitive RhoA pathways. Arterioscler Thromb Vasc Biol 2008; 28: 1511-1518.
49. Batenburg WW, Jansen PM, van den Bogaerdt AJ, Danser AHJ: Angiotensin II-aldosterone interaction in human coronary microarteries involves GPR30, EGFR, and endothelial NO synthase. Cardiovasc Res 2012; 94: 136-143.
50. Lemarie CA, Simeone SM, Nikonova A, Ebrahimian T, Deschenes ME, Coffman TM, Paradis P, Schiffrin EL: Aldosterone-induced activation of signaling pathways requires activity of angiotensin type 1a receptors. Circ Res 2009; 105: 852-859.
51. Lariviere R, Thibault G, Schiffrin EL: Increased endothelin-1 content in blood vessels of deoxycorticosterone acetate-salt hypertensive but not in spontaneously hypertensive rats. Hypertension 1993; 21: 294-300.
52. Schiffrin EL, Lariviere R, Li JS, Sventek P, Touyz RM: Deoxycorticosterone acetate plus salt induces overexpression of vascular endothelin-1 and severe vascular hypertrophy in spontaneously hypertensive rats. Hypertension 1995; 25: 769-773.
53. Amiri F, Virdis A, Neves MF, Iglarz M, Seidah NG, Touyz RM, Reudelhuber TL, Schiffrin EL: Endothelium-restricted overexpression of human endothelin-1 causes vascular remodeling and endothelial dysfunction. Circulation 2004; 110: 2233-2240.
54. Schiffrin EL, Sventek P, Li JS, Turgeon A, Reudelhuber T: Antihypertensive effect of an endothelin receptor antagonist in DOCAsalt spontaneously hypertensive rats. Br J Pharmacol 1995; 115: 1377-1381.
55. Li JS, Turgeon A, Schiffrin EL: Effect of chronic treatment with two different ET(A) selective endothelin receptor antagonists on blood pressure and small artery structure of deoxycorticosterone acetate (DOCA)-salt hypertensive rats. Am J Hypertens 1998; 11: 554-562.
56. Pu Q, Neves MF, Virdis A, Touyz RM, Schiffrin EL: Endothelin antagonism on aldosterone-induced oxidative stress and vascular remodeling. Hypertension 2003; 42: 49-55.
57. Stow LR, Gumz ML, Lynch IJ, Greenlee MM, Rudin A, Cain BD, Wingo CS: Aldosterone modulates steroid receptor binding to the endothelin-1 gene (edn1). J Biol Chem 2009; 284: 30087-30096.
58. Wehling M, Spes CH, Win N, Janson CP, Schmidt BM, Theisen K, Christ M: Rapid cardiovascular action of aldosterone in man. J Clin Endocrinol Metab 1998; 83: 3517-3522.
59. Schmidt BM, Montealegre A, Janson CP, Martin N, Stein-Kemmesies C, Scherhag A, Feuring M, Christ M, Wehling M: Short term cardiovascular effects of aldosterone in healthy male volunteers. J Clin Endocrinol Metab 1999; 84: 3528-3533.
60. Schmidt BM, Oehmer S, Delles C, Bratke R, Schneider MP, Klingbeil A, Fleischmann EH, Schmieder RE: Rapid nongenomic effects of aldosterone on human forearm vasculature. Hypertension 2003; 42: 156-160.
61. Gunaruwan P, Schmitt M, Sharman J, Lee L, Struthers A, Frenneaux M: Effects of aldosterone on forearm vasculature in treated chronic heart failure. Am J Cardiol 2005; 95: 412-414.
62. Schmidt BM, Sammer U, Fleischmann I, Schlaich M, Delles C, Schmieder RE: Rapid nongenomic effects of aldosterone on the renal vasculature in humans. Hypertension 2006; 47: 650-655.
63. Liu SL, Schmuck S, Chorazcyzewski JZ, Gros R, Feldman RD: Aldosterone regulates vascular reactivity: short-term effects mediated by phosphatidylinositol 3-kinase-dependent nitric oxide synthase activation. Circulation 2003; 108: 2400-2406.
64. Michea L, Delpiano AM, Hitschfeld C, Lobos L, Lavandero S, Marusic ET: Eplerenone blocks nongenomic effects of aldosterone on the Na +/H + exchanger, intracellular Ca 2+ levels, and vasoconstriction in mesenteric resistance vessels. Endocrinology 2005; 146: 973-980.
65. Yamada M, Kushibiki M, Osanai T, Tomita H, Okumura K: Vasoconstrictor effect of aldosterone via angiotensin II type 1 (AT1) receptor: possible role of AT1 receptor dimerization. Cardiovasc Res 2008; 79: 169-178.
66. Gros R, Ding Q, Sklar LA, Prossnitz EE, Arterburn JB, Chorazyczewski J, Feldman RD: GPR30 expression is required for the mineralocorticoid receptor-independent rapid vascular effects of aldosterone. Hypertension 2011; 57: 442-451.
67. Christ M, Douwes K, Eisen C, Bechtner G, Theisen K, Wehling M: Rapid effects of aldosterone on sodium transport in vascular smooth muscle cells. Hypertension 1995; 25: 117-123.
68. Wehling M, Neylon CB, Fullerton M, Bobik A, Funder JW: Nongenomic effects of aldosterone on intracellular Ca 2+ in vascular smooth muscle cells. Circ Res 1995; 76: 973-979.
69. Gros R, Ding Q, Armstrong S, O'Neil C, Pickering JG, Feldman RD: Rapid effects of aldosterone on clonal human vascular smooth muscle cells. Am J Physiol Cell Physiol 2007; 292:C788-C794.
70. Ishizawa K, Izawa Y, Ito H, Miki C, Miyata K, Fujita Y, Kanematsu Y, Tsuchiya K, Tamaki T, Nishiyama A, et al: Aldosterone stimulates vascular smooth muscle cell proliferation via big mitogen-activated protein kinase 1 activation. Hypertension 2005; 46: 1046-1052.
71. Ingelsson E, Pencina MJ, Tofler GH, Benjamin EJ, Lanier KJ, Jacques PF, Fox CS, Meigs JB, Levy D, Larson MG, et al: Multimarker approach to evaluate the incidence of the metabolic syndrome and longitudinal changes in metabolic risk factors: the Framingham Offspring Study. Circulation 2007; 116: 984-992.
72. Rossi GP, Belfiore A, Bernini G, Fabris B, Caridi G, Ferri C, Giacchetti G, Letizia C, Maccario M, Mannelli M, et al: Body mass index predicts plasma aldosterone concentrations in overweight-obese primary hypertensive patients. J Clin Endocrinol Metab 2008; 93: 2566-2571.
73. Bentley-Lewis R, Adler GK, Perlstein T, Seely EW, Hopkins PN, Williams GH, Garg R: Body mass index predicts aldosterone production in normotensive adults on a highsalt diet. J Clin Endocrinol Metab 2007; 92: 4472-4475.
74. Goodfriend TL, Kelley DE, Goodpaster BH, Winters SJ: Visceral obesity and insulin resistance are associated with plasma aldosterone levels in women. Obes Res 1999; 7: 355-362.
75. Petrasek D, Jensen G, Tuck M, Stern N: In vitro effects of insulin on aldosterone production in rat zona glomerulosa cells. Life Sci 1992; 50: 1781-1787.
76. Jeon JH, Kim KY, Kim JH, Baek A, Cho H, Lee YH, Kim JW, Kim D, Han SH, Lim JS, et al: A novel adipokine CTRP1 stimulates aldosterone production. FASEB J 2008; 22: 1502-1511.
77. Goodfriend TL, Ball DL, Raff H, Bruder ED, Gardner HW, Spiteller G: Oxidized products of linoleic acid stimulate adrenal steroidogenesis. Endocr Res 2002; 28: 325-330.
78. Ehrhart-Bornstein M, Lamounier-Zepter V, Schraven A, Langenbach J, Willenberg HS, Barthel A, Hauner H, McCann SM, Scherbaum WA, Bornstein SR: Human adipocytes secrete mineralocorticoid-releasing factors. Proc Natl Acad Sci USA 2003; 100: 14211-14216.
79. Briones AM, Cat AN, Callera GE, Yogi A, Burger D, He Y, Correa JW, Gagnon AM, Gomez-Sanchez CE, Gomez-Sanchez EP, et al: Adipocytes produce aldosterone through calcineurin-dependent signaling pathways: implications in diabetes mellitus-associated obesity and vascular dysfunction. Hypertension 2012; 59: 1069-1078.
80. Nguyen Dinh Cat A, Briones AM, Callera GE, Yogi A, He Y, Montezano AC, Touyz RM: Adipocyte-derived factors regulate vascular smooth muscle cells through mineralocorticoid and glucocorticoid receptors. Hypertension 2011; 58: 479-488.
81. Sherajee SJ, Fujita Y, Rafiq K, Nakano D, Mori H, Masaki T, Hara T, Kohno M, Nishiyama A, Hitomi H: Aldosterone induces vascular insulin resistance by increasing insulin-like growth factor-1 receptor and hybrid receptor. Arterioscler Thromb Vasc Biol 2012; 32: 257-263.
82. Hitomi H, Kiyomoto H, Nishiyama A, Hara T, Moriwaki K, Kaifu K, Ihara G, Fujita Y, Ugawa T, Kohno M: Aldosterone suppresses insulin signaling via the downregulation of insulin receptor substrate-1 in vascular smooth muscle cells. Hypertension 2007; 50: 750-755.
83. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309-1321.
84. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J: The effect of spironolactone on morbidity and mortality in patients with severe heart failure-Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-717.
85. Savoia C, Touyz RM, Amiri F, Schiffrin EL: Selective mineralocorticoid receptor blocker eplerenone reduces resistance artery stiffness in hypertensive patients. Hypertension 2008; 51: 432-439.
86. Amar L, Azizi M, Menard J, Peyrard S, Watson C, Plouin PF: Aldosterone synthase inhibition with LCI699: a proof-of-concept study in patients with primary aldosteronism. Hypertension 2010; 56: 831-838.
87. Calhoun DA, White WB, Krum H, Guo W, Bermann G, Trapani A, Lefkowitz MP, Menard J: Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, doubleblind, placebo-and active-controlled phase 2 trial. Circulation 2011; 124: 1945-1955.